85
Participants
Start Date
September 18, 2015
Primary Completion Date
March 25, 2019
Study Completion Date
March 25, 2019
ABBV-085
Administered as an intravenous infusion in 28-day dosing cycles.
Virginia Cancer Specialists /ID# 148584, Fairfax
Duke Univ Med Ctr /ID# 148200, Durham
Hospital Univ Ramon y Cajal /ID# 150799, Madrid
Fundacion Jimenez Diaz /ID# 148564, Madrid
Hosp Univ Madrid Sanchinarro /ID# 146039, Madrid
Carolina BioOncology Institute /ID# 148583, Huntersville
Greenville Hospital System /ID# 148652, Greenville
Washington University-School of Medicine /ID# 151348, St Louis
Mary Crowley Cancer Research /ID# 148580, Dallas
Univ TX, MD Anderson /ID# 147681, Houston
South Texas Accelerated Research Therapeutics /ID# 141715, San Antonio
Univ of Colorado Cancer Center /ID# 148581, Aurora
Mayo Clinic Arizona /ID# 148582, Phoenix
University of California, Los Angeles /ID# 148586, Los Angeles
Gustave Roussy /ID# 150300, Villejuif
Scottsdale Healthcare /ID# 151349, Scottsdale
University of Chicago /ID# 148579, Chicago
Dana-Farber Cancer Institute /ID# 143782, Boston
NYU Langone Medical Center /ID# 150786, New York
University of Pennsylvania /ID# 148576, Philadelphia
Lead Sponsor
AbbVie
INDUSTRY